{"DataElement":{"publicId":"5025008","version":"1","preferredName":"Patient Phosphorylated Epidermal Growth Factor Receptor Staining Not Evaluable Reason Category","preferredDefinition":"The choice of reasons why a patient was not evaluable for epidermal growth factor receptor protein (EGFR) bearing phosphorylated tyrosine residues within the 194 amino acids of the carboxyl-terminal intracellular domain of the protein staining.","longName":"PT_PHO_EGFR_STN_N_EVL_RSN_CAT","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"5024965","version":"1","preferredName":"Patient Phosphorylated Epidermal Growth Factor Receptor Staining Evaluable Disease Assessment","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Epidermal growth factor receptor protein (EGFR) bearing phosphorylated tyrosine residues within the 194 amino acids of the carboxyl-terminal intracellular domain of the protein. Five ligand-dependent autophosphorylation sites have been identified; overexpression or mutation of EGFR can decouple ligand-binding from autophosphorylation and the subsequent activation of downstream signaling pathways. The presence of phosphorylated EGFR in a malignant tumor is generally correlated with poor prognosis and could be used as a predictive biomarker to identify individuals who may respond to EGFR-tyrosine kinase inhibitor treatment._Discoloration of patient tissue(s) produced by absorption of, or contact with, foreign matter, such as with medical dyes._Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial._The final result of a determination of the value, significance, or extent of.","longName":"2233604v1.0:5024963v1.0","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5024963","version":"1","preferredName":"Phosphorylated Epidermal Growth Factor Receptor Staining Evaluable Disease Assessment","preferredDefinition":"Epidermal growth factor receptor protein (EGFR) bearing phosphorylated tyrosine residues within the 194 amino acids of the carboxyl-terminal intracellular domain of the protein. Five ligand-dependent autophosphorylation sites have been identified; overexpression or mutation of EGFR can decouple ligand-binding from autophosphorylation and the subsequent activation of downstream signaling pathways. The presence of phosphorylated EGFR in a malignant tumor is generally correlated with poor prognosis and could be used as a predictive biomarker to identify individuals who may respond to EGFR-tyrosine kinase inhibitor treatment.:Discoloration of patient tissue(s) produced by absorption of, or contact with, foreign matter, such as with medical dyes.:Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial.:The final result of a determination of the value, significance, or extent of.","longName":"C123765:C50753:C8503:C25217","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phosphorylated Epidermal Growth Factor Receptor","conceptCode":"C123765","definition":"Epidermal growth factor receptor protein (EGFR) bearing phosphorylated tyrosine residues within the 194 amino acids of the carboxyl-terminal intracellular domain of the protein. Five ligand-dependent autophosphorylation sites have been identified; overexpression or mutation of EGFR can decouple ligand-binding from autophosphorylation and the subsequent activation of downstream signaling pathways. The presence of phosphorylated EGFR in a malignant tumor is generally correlated with poor prognosis and could be used as a predictive biomarker to identify individuals who may respond to EGFR-tyrosine kinase inhibitor treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Staining","conceptCode":"C50753","definition":"Discoloration of patient tissue(s) produced by absorption of, or contact with, foreign matter, such as with medical dyes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Evaluable Disease","conceptCode":"C8503","definition":"Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2097F6A4-B078-8D8E-E050-BB89AD435B17","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2097F6A4-B089-8D8E-E050-BB89AD435B17","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5024989","version":"1","preferredName":"Not Evaluable Reason Category","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction._Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial._An explanation of the cause of some phenomenon or action._A grouping of items based on some commonality or by user defined characteristics.","longName":"5024989v1.0","context":"DCP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other, specify","valueDescription":"Other Specify","ValueMeaning":{"publicId":"4188777","version":"1","preferredName":"Other Specify","longName":"4188777","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Be specific about something; define clearly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3CC9DDB-CE4D-9879-E040-BB89AD430A03","latestVersionIndicator":"Yes","beginDate":"2014-03-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"209716FA-F6E8-C0C4-E050-BB89AD4346BF","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"Specimen lost","valueDescription":"Lost Specimen","ValueMeaning":{"publicId":"5024990","version":"1","preferredName":"Lost Specimen","longName":"5024990","preferredDefinition":"Parted with; no longer held or possessed; incapable of being recovered or regained.: A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lost","conceptCode":"C25560","definition":"Parted with; no longer held or possessed; incapable of being recovered or regained.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specimen","conceptCode":"C19157","definition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"209716FA-F6F6-C0C4-E050-BB89AD4346BF","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"209716FA-F70F-C0C4-E050-BB89AD4346BF","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"Assay failed","valueDescription":"Failed Assay","ValueMeaning":{"publicId":"5024991","version":"1","preferredName":"Failed Assay","longName":"5024991","preferredDefinition":"Having undergone failure; did not accomplish the intended purpose.: A qualitative or quantitative analysis performed to determine the amount of a particular constituent in a sample or the biological or pharmacological potency of a drug.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Failed","conceptCode":"C44281","definition":"Having undergone failure; did not accomplish the intended purpose.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assay","conceptCode":"C60819","definition":"A qualitative or quantitative analysis performed to determine the amount of a particular constituent in a sample or the biological or pharmacological properties of a drug.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"209716FA-F71C-C0C4-E050-BB89AD4346BF","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"209716FA-F735-C0C4-E050-BB89AD4346BF","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"Insufficient tissue","valueDescription":"Inadequate Tissue","ValueMeaning":{"publicId":"5024992","version":"1","preferredName":"Inadequate Tissue","longName":"5024992","preferredDefinition":"Not meeting a quantitative or qualitative measure necessary for a requirement.: An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inadequate","conceptCode":"C69177","definition":"Not meeting a quantitative or qualitative measure necessary for a requirement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tissue","conceptCode":"C12801","definition":"An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"209716FA-F73F-C0C4-E050-BB89AD4346BF","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"209716FA-F758-C0C4-E050-BB89AD4346BF","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"No positive pixels","valueDescription":"No Positive Pixel","ValueMeaning":{"publicId":"5024993","version":"1","preferredName":"No Positive Pixel","longName":"5024993","preferredDefinition":"The non-affirmative response to a question.: Involving advantage or good.: The smallest resolvable rectangular area of an image, either on a screen or stored in memory.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Positive","conceptCode":"C25246","definition":"Involving advantage or good.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pixel","conceptCode":"C48367","definition":"The smallest resolvable rectangular area of an image, either on a screen or stored in memory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"209716FA-F766-C0C4-E050-BB89AD4346BF","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"209716FA-F77F-C0C4-E050-BB89AD4346BF","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5024988","version":"1","preferredName":"Negation Evaluable Disease Reason Category","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.:Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial.:An explanation of the cause of some phenomenon or action.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C25594:C8503:C25638:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Evaluable Disease","conceptCode":"C8503","definition":"Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"209716FA-F6C1-C0C4-E050-BB89AD4346BF","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"209716FA-F6D2-C0C4-E050-BB89AD4346BF","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"MAESKEB","dateModified":"2016-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"4528051","version":"1","longName":"MAY2013-02-02","context":"DCP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If no, specify","type":"Preferred Question Text","description":"If no, specify","url":null,"context":"DCP"}],"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"209716FA-F7C0-C0C4-E050-BB89AD4346BF","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"MAESKEB","dateModified":"2016-04-19","changeDescription":"Curated for MAY2013-02-02","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}